Patents by Inventor Kim Lynette Askew

Kim Lynette Askew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10493135
    Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: December 3, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W. Charles O'Neill
  • Patent number: 10413597
    Abstract: Methods for treating the central nervous system (CNS) in a human patient with mucopolysaccharidosis (MPS) MB who has an intact blood brain barrier, comprising intravenous administration of recombinant NaGlu.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 17, 2019
    Assignee: ALEXION PHARMACEUTICALS, INC.
    Inventors: Anthony Quinn, Sandra Rojas-Caro, Anthony Rossomando, Robert John Lyng, Kim Lynette Askew, Nelson Hsia, Kiran Patki
  • Publication number: 20180318400
    Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
    Type: Application
    Filed: December 18, 2015
    Publication date: November 8, 2018
    Inventors: Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W.Charles O'Neill
  • Publication number: 20170216413
    Abstract: Methods for treating the central nervous system (CNS) in a human patient with mucopolysaccharidosis (MPS) MB who has an intact blood brain barrier, comprising intravenous administration of recombinant NaGlu.
    Type: Application
    Filed: September 29, 2015
    Publication date: August 3, 2017
    Inventors: Anthony Quinn, Sandra Rojas-Caro, Anthony Rossomando, Robert John Lyng, Kim Lynette Askew, Nelson Hsia, Kiran Patki
  • Patent number: RE49529
    Abstract: The present invention provides a method of treating NPP1 deficiency or NPP1-associated disease such as idiopathic infantile arterial calcification (IIAC), pseudoxanthoma elasticum, vascular calcification in chronic kidney disease (VCCKD), insulin resistance, hypophosphatemic rickets, myocardial ischemia, joint calcification, angioid streaks, and ossification of the posterior longitudinal ligament of the spine. The present invention provides a method for treating tissue calcification by administering soluble NPP1 to produce a transient increase in serum pyrophosphate levels.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: May 16, 2023
    Assignee: Inozyme Pharma, Inc.
    Inventors: Anthony Quinn, Nelson Hsia, Tayeba Khan, Kim Lynette Askew, Gregory Grabowski, Zhiliang Cheng, W. Charles O'Neill